Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Amarin Corporation PLC AMRN

Healthcare Drug Manufacturers - Major
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The... see more

Current News (NDAQ:AMRN)

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

GlobeNewswire 12 days ago

Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire February 25, 2026

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

GlobeNewswire February 23, 2026

Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

GlobeNewswire February 11, 2026

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

GlobeNewswire January 9, 2026

Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities

GlobeNewswire January 8, 2026

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

GlobeNewswire November 9, 2025

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

GlobeNewswire November 3, 2025

Amarin Reports Third Quarter 2025 Financial Results

GlobeNewswire October 29, 2025
View More News ››

Opinion & Analysis (NDAQ:AMRN)

Krill oil boom is real

Andrew Mickey June 3, 2011
View More Opinion ››

Bullboard Posts (NDAQ:AMRN)

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
Tinekerensen - April 13, 2023

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

   
Tinekerensen - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >>
Tinekerensen - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

 
Tinekerensen - June 2, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

Tinekerensen - May 11, 2022

Lucid-MS for Multiple Sclerosis Treatment

<< View Post To Watch Video >>
Tinekerensen - April 30, 2022
View more Bullboard ››

Nurcapital Common Stock

Nurcapital Common Stock

Nurcapital Corporation Ltd. is a Canada-based capital pool company. The Company is engaged in identifying and evaluating ...
View More »

Podcasts